Cristina Csimma
Director/Board Member at SYNCONA LIMITED
Net worth: 5 125 $ as of 31/07/2023
Profile
Cristina Csimma founded Cydan II, Inc., where she worked as Director in 2014.
Dr. Csimma also currently works at Caraway Therapeutics, Inc., as Chairman from 2019 and Syncona Ltd., as Non-Executive Director from 2022.
Dr. Csimma also formerly worked at Cydan LLC, as President & Chief Executive Officer, Forendo Pharma Oy, as Chairman from 2020 to 2021, Exonics Therapeutics, Inc., as Executive Chairman from 2016 to 2017, Catalent JNP, Inc., as Independent Director from 2010 to 2018, Genetics Institute LLC, as Associate Director-Clinical Research from 1988 to 2000, Idera Pharmaceuticals, Inc., as Independent Director, Seneca Biopharma, Inc., as Independent Director, Wyeth-Ayerst Research, as Director-Clinical Research & Development in 2001, Pfizer Pharmaceuticals, Inc., as Senior Director-Translational Research in 2006, T1D Exchange, as Director from 2018 to 2020, Vtesse, Inc., as Independent Director from 2014 to 2017, Palisade Bio, Inc., as Independent Director, Aceragen, Inc., as Independent Director from 2019 to 2023, Virdante Pharmaceuticals, Inc., as Vice President-Drug Development from 2009 to 2011, Dana-Farber Cancer Institute, Inc., as Principal, and Clarus Ventures LLC, as Principal.
Dr. Csimma received her undergraduate degree and doctorate degree from Massachusetts College of Pharmacy & Health Science and graduate degree from Northeastern University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
PALISADE BIO, INC.
0.10% | 15/03/2024 | 12,844 ( 0.10% ) | 5 125 $ | 31/03/2024 |
ACERAGEN, INC.
-.--% | 19/07/2023 | 0 ( -.--% ) | - $ | 31/07/2023 |
Cristina Csimma active positions
Companies | Position | Start |
---|---|---|
SYNCONA LIMITED | Director/Board Member | 01/02/2022 |
Caraway Therapeutics, Inc.
Caraway Therapeutics, Inc. BiotechnologyHealth Technology Caraway Therapeutics, Inc. provides heathcare services. The company was founded by Timothy Harris, Wade Harper ,Ivan Dikic ,Tony Hyman and is headquartered in Cambridge, MA. | Chairman | 01/04/2019 |
Former positions of Cristina Csimma
Companies | Position | End |
---|---|---|
PALISADE BIO, INC. | Director/Board Member | 09/02/2024 |
ACERAGEN, INC. | Director/Board Member | 15/08/2023 |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Chairman | 01/12/2021 |
T1D Exchange
T1D Exchange Pharmaceuticals: MajorHealth Technology T1D Exchange is a nonprofit organization that was established in 2010 with initial and ongoing support from the Leona M. and Harry B. Helmsley Charitable Trust. T1D Exchange is based in Boston, MA. The non-profit company is dedicated to improving outcomes for the entire T1D population through real-world evidence and clinical data collection and analysis. T1D Exchange is a leading provider of real-world evidence, identifying gaps in data and redefining best practices to improve the lives of those living with T1D. The company actively supports quality improvement and innovation through its quality improvement collaborative, patient registry, and data-oriented research services. David Walton has been the CEO of the company since 2018. | Director/Board Member | 01/01/2020 |
JUNIPER PHARMACEUTICALS INC | Chief Tech/Sci/R&D Officer | - |
Training of Cristina Csimma
Massachusetts College of Pharmacy & Health Science | Doctorate Degree |
Northeastern University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
PALISADE BIO, INC. | Health Technology |
ACERAGEN, INC. | Health Technology |
Private companies | 17 |
---|---|
Catalent JNP, Inc.
Catalent JNP, Inc. Pharmaceuticals: MajorHealth Technology Catalent JNP, Inc. engages in the research and development of drugs and therapeutics. It offers analytical characterization and pre-formulation testing; formulation development; and clinical manufacturing of capsules and tablets. The company was founded in December 1986 and is headquartered in Somerset, NJ. | Health Technology |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Virdante Pharmaceuticals, Inc.
Virdante Pharmaceuticals, Inc. Medical DistributorsDistribution Services Virdante Pharmaceuticals, Inc. develops and commercializes drugs for auto-immune and inflammatory disorders. The company's products incorporate a proprietary 'sialic switch' technology to improve the anti-inflammatory properties of antibodies. It was founded in 2008 and is headquartered in Cambridge, MA. | Distribution Services |
Syncona Ltd.
Syncona Ltd. Investment Trusts/Mutual FundsMiscellaneous Syncona Ltd. is a closed-end investment fund. It engages in delivering returns from investments in long and alternative investment funds across multiple asset classes and targets. The company was founded on August 14, 2012, and is headquartered in St. Peter Port, the United Kingdom. | Miscellaneous |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Health Services |
Seneca Biopharma, Inc.
Seneca Biopharma, Inc. BiotechnologyHealth Technology Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD. | Health Technology |
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Wyeth-Ayerst Research | |
Pfizer Pharmaceuticals, Inc.
Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Pharmaceuticals, Inc. is an American company that manufactures pharmaceutical products. | Health Technology |
Cydan II, Inc.
Cydan II, Inc. Pharmaceuticals: GenericHealth Technology Cydan II, Inc. develops and commercializes drugs for orphan and diseases. The firm evaluates products for treating rare diseases with high unmet medical need to start multiple companies to develop such therapies. The company was founded by Cristina Csimma, James G. McArthur, Deborah S. Geraghty and Christoph M. Adams in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Cydan LLC
Cydan LLC Medical DistributorsDistribution Services Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA. | Distribution Services |
T1D Exchange
T1D Exchange Pharmaceuticals: MajorHealth Technology T1D Exchange is a nonprofit organization that was established in 2010 with initial and ongoing support from the Leona M. and Harry B. Helmsley Charitable Trust. T1D Exchange is based in Boston, MA. The non-profit company is dedicated to improving outcomes for the entire T1D population through real-world evidence and clinical data collection and analysis. T1D Exchange is a leading provider of real-world evidence, identifying gaps in data and redefining best practices to improve the lives of those living with T1D. The company actively supports quality improvement and innovation through its quality improvement collaborative, patient registry, and data-oriented research services. David Walton has been the CEO of the company since 2018. | Health Technology |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Health Technology |
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Health Technology |
Exonics Therapeutics, Inc.
Exonics Therapeutics, Inc. BiotechnologyHealth Technology Exonics Therapeutics, Inc. develops therapies for neuromuscular diseases. It also develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded by Eric N. Olson in February 2017 and is headquartered in Cambridge, MA. | Health Technology |
Caraway Therapeutics, Inc.
Caraway Therapeutics, Inc. BiotechnologyHealth Technology Caraway Therapeutics, Inc. provides heathcare services. The company was founded by Timothy Harris, Wade Harper ,Ivan Dikic ,Tony Hyman and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Cristina Csimma